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Abstract Heart failure (HF) poses a heavy burden on
patients, their families and society. The syndrome of HF
comes in two types: with reduced ejection fraction
(HFrEF) and preserved ejection fraction (HFpEF). The
latter is on the increase and predominantly present in
women, especially the older ones. There is an urgent need
for mortality-reducing drugs in HFpEF, a disease affecting
around 5 % of those aged 65 years and over. HFpEF
develops in patients with risk factors and comorbidities
such as obesity, hypertension, diabetes, COPD, but also
preeclampsia. These conditions are likely to drive micro-
vascular disease with involvement of the coronary micro-
vasculature, which may eventually evolve into HFpEF.
Currently, the diagnosis of HFPEF relies mainly on echo-
cardiography. There are no biomarkers that can help di-
agnose female microvascular disease or facilitate the
diagnosis of (early stages of) HFpEF. Recently a Dutch
consortium was initiated, Queen of Hearts, with support
from the Netherlands Heart Foundation, with the aim to
discover and validate biomarkers for diastolic dysfunction
and HFpEF in women. These biomarkers come from
innovative blood-derived sources such as extracellular
vesicles and circulating cells. Within the Queen of Hearts
consortium, we will pursue female biomarkers that have
the potential for further evolution in assays with point of
care capabilities. As a spin-off, the consortium will gain
knowledge on gender-specific pathology of HFpEF, pos-
sibly opening up novel treatment options.
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Women and heart failure with preserved ejection fraction
Cardiovascular disease (CVD) is the number one killer among
women worldwide. Controversially, women have been under-
represented in most clinical trials on cardiovascular disease.
The most striking differences in the prevalence of CVD be-
tween men and women are visualised in the syndrome of heart
failure (HF).
Among older patients in developed countries, HF probably
represents the greatest health burden with an estimated 23
million people with HF worldwide, with nearly 50 % of them
women [1]. HF is a clinical syndrome characterised by symp-
toms and signs of volume overload and cardiac adaptation,
where cardiac dysfunction is responsible for failure of the
heart to supply adequate peripheral oxygen delivery to meet
the requirements of metabolising tissues. Without myocardial
damage in the history, the lifetime risk of HF at age 40 is
estimated to be 1 in 6 for women, and 1 to 9 in men [1]. Most
studies agree that women suffer from a worse quality of life
when HF has been diagnosed [2]. Despite this, survival for HF
seems to be better for women [3] underlining the gender
differences in development and progression of HF.
The diagnosis of HF is based on suggestive symptoms and
signs and structural or functional abnormalities on echocardi-
ography [4, 5]. Patients with HF and a preserved ejection
fraction (HFpEF) have similar symptoms and signs to those
with reduced ejection fraction (HFrEF). Around 50 % of the
patients with HF suffer from HFpEF, also referred to as
diastolic HF. The aetiology of HFrEF and HFpEF differs,
and prognostically beneficial therapy for HFpEF is lacking,
which is in sharp contrast to HFrEF.
HFpEF is associated with diastolic left ventricular dysfunc-
tion that involves reduced left ventricular relaxation and in-
creased left ventricular stiffness with a relatively normal ejec-
tion fraction of 50 % or more [6]. A consistent and unex-
plained finding among population-based studies is that
women outnumber men in the syndrome of HFpEF with
an impressive 2:1 ratio.
Natriuretic peptides are useful biomarkers with added di-
agnostic value on top of clinical assessment [7], although with
much better negative predictive values (exclusion of HF) than
positive predictive values (‘confirming’ HF) [4]. Importantly,
however, in HFpEF natriuretic peptide levels can be at normal
levels, especially in the early phases of the disease, when the
patient has not exercised in the last couple of days, and in the
absence of signs of water and salt retention. Screening studies
showed that unrecognised HF is common in high-risk groups
such as older community-dwelling individuals with chronic
obstructive pulmonary disease (COPD) and diabetes type 2,
with prevalence rates of undetected HF of 20.5 and 27.7 %,
respectively [8, 9]. In those with COPD aged 65 years and
over and novel screen-detected heart failure, 50 % had
HFpEF. In those with type 2 diabetes aged 60 years and over
with screen-detected HF, 83 % had HFpEF. Interestingly, the
prevalence of unrecognised HFpEF in patients with type 2
diabetes was much higher in women than in men (28.0 vs.
18.4 %), and this was in all age strata [9].
The prevalence of HFpEF is around 3–5 % in the open
population aged 65 years and over, and 4–6 % in men and 8–
10% in women for individuals of 80 years and older [10]. Due
to the ageing (female) population, HFpEF is a growing epi-
demic with poor treatment options resulting in more elderly
women living with disabling HFpEF [6].
Comorbidities
Comorbidities have been strongly associated with HF but
differ between HFrEF and HFpEF. In a predominantly male
HF cohort it was shown that there was a higher non-cardiac
comorbidity burden in HFpEF patients compared with HFrEF
patients [11].
Differences in prevalence of comorbidities also exist be-
tween men and women with HFpEF. Women are generally
older and have a higher likelihood of having diabetes, system-
ic hypertension and systolic blood pressure with a similar
body mass index to men [12].
Diabetes type 2
Diabetes is one of the main risk factors for developing
HFpEF. This is evident in Western society but even more
eminent in Asian people. The prevalence of diabetes is
rapidly rising which is likely to push up the incidence of
HFpEF in the coming decades. Astounding prevalence
rates of diastolic dysfunction between 27 and 70 % have
been reported in the growing diabetics [13]. As already
mentioned, the prevalence of unknown HFpEF in patients
with type 2 diabetes and aged 60 years or over was clearly
higher in women than men [9].
Hypertension and preeclampsia
Hypertension is a major risk factor for HF as it increases
cardiac workload. Hypertension is more prevalent in HFpEF
than in HFrEF [11]. Systemic hypertension is very common
(83 %) and often severe in HFpEF patients [13]. The Fra-
mingham Heart Study already identified hypertension as the
greatest population attributable risk for the development of HF
with 39 % in men and 59 % in women [14]. Furthermore,
among those with hypertension, diabetes poses an additional
risk for the development of HF, which is higher in women
(HR 3.57 95 % CI (2.59–4.94) than men (HR 1.78 95 % CI
(1.23–2.59)).
Preeclampsia is the occurrence of both hypertension and
proteinuria during pregnancy and is associated with the
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development of hypertension, diabetes type 2 and obesity later
in life. Although the exact pathophysiology of preeclampsia is
unclear, it is already known that it can result in endothelial
dysfunction during the pregnancy [15]. Preeclampsia is a
typical female risk factor for the development of HFpEF
which has been underexposed.
Preeclampsia can already be associated with diastolic
dysfunction during pregnancy, but also 1 year after
pregnancy. In a small cohort of women with preterm
preeclampsia, diastolic dysfunction persisted up to 1 year
postpartum in 51 % of the women [16]. In the women
with term preeclampsia, diastolic dysfunction decreased
from 40 % during pregnancy to 16 % after 1 year post-
partum, while in controls this was approximately 5 % at
both time points. Moreover, the risk of developing hy-
pertension in women with preeclampsia was higher
2 years postpartum than in women without preeclamp-
sia. Preliminary data suggest that preeclampsia is asso-
ciated with placenta dysfunction and is a trigger for
accelerated microvascular endothelial dysfunction [17].
Microvascular disease as underlying cause of HFpEF
Diabetes, hypertension and preeclampsia have in common
that they accelerate systemic and coronary microvascular
dysfunction, which is highly associated with the development
of HFpEF. This relation seems to be stronger in women. In
contrast, HFrEF is typically myocardial infarction with eccen-
tric remodelling as a result [4]. A dilated left ventricle, a
reduction in stroke volume and left ventricular ejection frac-
tion can be found.
HFpEF seems thus to be a different phenotype within the
HF spectrum. According to a recently postulated paradigm,
HFpEF develops from a ‘systemic proinflammatory state’
induced by certain comorbidities [17].
Comorbidities such as diabetes, obesity, COPD and
preeclampsia can induce a systemic inflammatory state
and subsequent systemic microvascular endothelial dys-
function [17]. The proinflammatory state causes micro-
vascular endothelial dysfunction due to reduced bio-
availability of nitric oxide and concentric remodelling
of the left ventricle. In sharp contrast with HFrEF, well-
established evidence-based heart failure therapies such
as ACE inhibitors, angiotensin receptor blockers, miner-
alocorticoid receptor antagonists, and beta-blockers did
not significantly improve the prognosis in HFpEF. More
‘upstream’ treatment of HFpEF seems to be a better
option, but for that the pathways to diastolic dysfunc-
tion and finally HFpEF should be more clearly
unravelled.
The Queen of Hearts concept
The Queen of Hearts program (http://www.queen-of-hearts.
eu) hypothesises that comorbidities such as diabetes, COPD,
and preeclampsia share a common pathway to the
development of HFpEF from which gender-specific bio-
markers in women can be deduced. By using follow-up echo-
cardiographic data in women who have experienced pre-
eclampsia, we hope to detect novel biomarkers that could be
helpful in clinical practice for individual risk stratification and
diagnostic and prognostic prediction.
The Queen of Hearts program (Fig. 1) aims to discover
novel biomarkers from blood-derived sources (miRNA,
extracellular vesicles, micro-environment, circulating cells)
for sex-specific biomarker discovery based on microvascular
pathology. This approach will also help in understanding the
underlying pathogenesis of diastolic dysfunction and HFpEF.
The ultimate goal is to facilitate female-specific diagnostic
and prognostic blood-based tests for diastolic dysfunction and
HFpEF in the clinical setting.
Global and future perspectives
From the WHO statistics report 2012 (http://www.who.int/
gho/publications/world_health_statistics/2012/en/) it is clear
that diabetes and hypertension are on the increase worldwide,
also affecting low income countries. Asia and Africa are
overtaking the Western world and as a result cardiovascular
diseases, including heart failure, are on the increase in these
parts of the world.
HFpEF in Asia
In contrast to the wealth of data regarding HFpEF in
Western populations, data are limited in Asian popula-
tions. The true prevalence of HFpEF in Asian commu-
nities is unknown, and may vary in different regions of
Asia. In Singapore, the proportion of HF patients with
HFpEF has been estimated at 22 % in a single-centre
study [18]—this is a lower proportion than that seen in
Western cohorts and remains to be confirmed in larger
prospective studies. One such study is the ongoing
Singapore Heart Failure Outcomes and Phenotypes
(SHOP) study [19]. Data in a subset of 50 Asian pa-
tients with HFpEF from the SHOP cohort showed that
these were more predominantly elderly (mean age
69 years) hypertensive women with a higher mean body
mass index compared with patients with HFrEF or
community-based controls without HF. Furthermore,
compared with age-matched community-based controls
without heart failure, patients with HFpEF had higher
median levels of growth differentiation factor 15, a
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member of the transforming growth factor-beta cytokine
superfamily and marker of cell injury and inflammation
(540 pg/ml vs 2529 pg/ml). This is consistent with a
systemic inflammatory response in Asian patients with
HFpEF. Larger prospective studies are underway across
Asia to further define the Asian phenotype of HF [20].
In addition, recognising the close link between
pregnancy-associated diseases and development of car-
diovascular diseases including HFpEF in women, a
combined clinical program integrating Obstetrics & Gy-
naecology and Cardiology has been set up in Singapore.
The combined study of these women from both disci-
plines provides the potential to elucidate shared novel
pathways between preeclampsia and HFpEF.
Next to these initiatives, Singapore has a comparable health
standard to the Netherlands and is inhabited by three Asian
ethnicities. The Queen of Hearts program aims to strongly
collaborate with this Asian country. Initiatives are being taken
for exchange of people and validation of new markers in
Singaporean cohorts.
Future perspectives
The number of older women with a history of hypertension
and diabetes will increase worldwide and thus, early risk
stratification and early and accurate diagnosis of HFpEF with
the help of novel blood markers could help to identify high-
risk patients, and provide the opportunity for novel treatment
options.
The Queen of Hearts program anticipates to discover novel
proteins and miRNAs that may improve risk stratification,
early diagnosis and provide novel treatment targets for
HFpEF, especially in well-established high-risk groups such
as women with diabetes or a history of preeclampsia. We will
Fig. 1 The Queen of Hearts
consortium consists of three
themes that are interconnected:
Discovery of biomarkers,
Pathogenesis and Validation in
clinical studies. Copied with
permission from www.queen-
of-hearts.eu
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collaborate with international cohorts of heart failure and
preeclampsia in Singapore and Asia.
The consortium will improve the knowledge on gender-
specific pathology of HFpEF.
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